Medimmune Limited

Elan Pharmaceuticals, Inc.

Aeres Biomedical, Ltd.

Other

Tarran Jones

David Gareth Williams

Jose William Saldanha

Mary M Bendig

Ted A Yednock

Olivier J Leger

David M Hilbert

Siobhan H O'Brien

Alison Levy

Siobhan O'brien

David G Williams

A chimeric mouse-human antibody for treatment of amyloid deposition diseases, pharmaceutical compositions comprising the antibody, methods and materials for producing the antibody, and methods for treating an amyloid deposition disease using the antibody and the pharmaceutical composition.

Chimeric antibodies for treatment of amyloid deposition diseases

Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and light chain variable region ('VK'). The FW regions may contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. The human or humanized VH framework regions may comprise one or more of the following residues: a valine at position 24 of FW1, a glycine at position 49 of FW2, and an asparagine at position 73 of FW3, numbered according to Kabat. Further provided are pharmaceutical and immunotherapeutic compositions, and methods using anti-CD22 antibodies that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases in humans, including B cell malignancies, autoimmune disease, GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder.

Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framework regions of the immunoglobulin light chain variable region ('VK'). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.

Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies

Humanized anti-VLA4 immunoglobulins

Growing community of inventors

Radlett, United Kingdom

Tarran Jones